Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Mesoblast Limited ( (AU:MSB) ) is now available.
Mesoblast Limited announced the cessation of 483,254 securities due to the lapse of conditional rights, as the conditions for these securities were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could influence investor perceptions regarding the company’s operational and financial strategies.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited operates in the biotechnology industry, focusing on the development and commercialization of innovative cellular medicines. The company specializes in regenerative medicine products aimed at treating complex diseases with significant unmet medical needs.
YTD Price Performance: -46.61%
Average Trading Volume: 5,353,171
Technical Sentiment Signal: Hold
Current Market Cap: A$2.11B
For an in-depth examination of MSB stock, go to TipRanks’ Overview page.